These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34773471)

  • 1. AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan).
    Winzely M; Jouppila A; Ramer G; Lux L; Lendl B; Barreiro K; Lassila R; Friedbacher G
    Anal Bioanal Chem; 2022 Jan; 414(2):1029-1038. PubMed ID: 34773471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation.
    Chen J; Verni CC; Jouppila A; Lassila R; Diamond SL
    Thromb Res; 2018 Sep; 169():143-151. PubMed ID: 30071479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenously administered APAC, a dual AntiPlatelet AntiCoagulant, targets arterial injury site to inhibit platelet thrombus formation and tissue factor activity in mice.
    Bonetti NR; Jouppila AS; Saeedi Saravi SS; Cooley BC; Pasterk L; Liberale LL; Gobbato S; Lüscher TF; Camici GG; Lassila RP; Beer JH
    Thromb Res; 2023 Aug; 228():163-171. PubMed ID: 37331119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antiplatelet and anticoagulant APAC prevents experimental ischemia-reperfusion-induced acute kidney injury.
    Tuuminen R; Jouppila A; Salvail D; Laurent CE; Benoit MC; Syrjälä S; Helin H; Lemström K; Lassila R
    Clin Exp Nephrol; 2017 Jun; 21(3):436-445. PubMed ID: 27405618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with APAC, a dual antiplatelet anticoagulant heparin proteoglycan mimetic, limits early collar-induced carotid atherosclerotic plaque development in Apoe
    Bot I; Delfos L; Hemme E; Bernabé Kleijn MNA; van Santbrink PJ; Foks AC; Kovanen PT; Jouppila A; Lassila R
    Atherosclerosis; 2024 Oct; 397():118567. PubMed ID: 39243663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Locally Acting Dual Antiplatelet and Anticoagulant (APAC) Targets Multiple Sites of Vascular Injury in an Experimental Porcine Model.
    Barreiro KA; Tulamo R; Jouppila A; Albäck A; Lassila R
    Eur J Vasc Endovasc Surg; 2019 Dec; 58(6):903-911. PubMed ID: 31708337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Functional Pharmacokinetic Profile of APAC, a Novel Intravascular Antiplatelet and Anticoagulant.
    Craige S; Jouppila A; Humphries B; Lassila R
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):453-462. PubMed ID: 34132685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mast cell-derived heparin proteoglycans as a model for a local antithrombotic.
    Lassila R; Jouppila A
    Semin Thromb Hemost; 2014 Nov; 40(8):837-44. PubMed ID: 25393636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment with a dual antiplatelet and anticoagulant (APAC) reduces ischemia-reperfusion injury in a mouse model of temporary middle cerebral artery occlusion-implications for neurovascular procedures.
    Denorme F; Frösen J; Jouppila A; Lindgren A; Resendiz-Nieves JC; Manninen H; De Meyer SF; Lassila R
    Acta Neurochir (Wien); 2024 Mar; 166(1):137. PubMed ID: 38485848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-like effect of a dual antiplatelet and anticoagulant (APAC) agent on red blood cell deformability and aggregation in an experimental model.
    Matrai AA; Varga A; Bedocs-Barath B; Vanyolos E; Orban-Kalmandi R; Loczi L; Bagoly Z; Jouppila A; Lassila R; Nemeth N; Deak A
    J Thromb Thrombolysis; 2024 Dec; 57(8):1329-1338. PubMed ID: 39231863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of arterial thrombosis using a novel heparin with enhanced antiplatelet activity and reduced anticoagulant activity.
    Poletti LF; Bird K; Harris RB; Marques D; Sobel M
    J Vasc Surg; 1997 Sep; 26(3):366-72. PubMed ID: 9308582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.
    Mehta AY; Mohammed BM; Martin EJ; Brophy DF; Gailani D; Desai UR
    J Thromb Haemost; 2016 Apr; 14(4):828-38. PubMed ID: 26748875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The type 2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress.
    Scaglione GL; Lancellotti S; Papi M; De Spirito M; Maiorana A; Baronciani L; Pagliari MT; Arcovito A; Di Stasio E; Peyvandi F; De Cristofaro R
    J Thromb Haemost; 2013 Sep; 11(9):1688-98. PubMed ID: 23819767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourier-Transform Atomic Force Microscope-Based Photothermal Infrared Spectroscopy with Broadband Source.
    Xie Q; Xu XG
    Nano Lett; 2022 Nov; 22(22):9174-9180. PubMed ID: 36368003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fourier Transform Infrared (FTIR) Spectroscopy, Ultraviolet Resonance Raman (UVRR) Spectroscopy, and Atomic Force Microscopy (AFM) for Study of the Kinetics of Formation and Structural Characterization of Tau Fibrils.
    Ramachandran G
    Methods Mol Biol; 2017; 1523():113-128. PubMed ID: 27975247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing multimer analysis of von Willebrand factor by single-molecule AFM imaging.
    Löf A; König G; Schneppenheim S; Schneppenheim R; Benoit M; Budde U; Müller JP; Brehm MA
    PLoS One; 2019; 14(1):e0210963. PubMed ID: 30645640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of antiplatelet or anticoagulant agents with in-hospital mortality among blunt torso trauma patients without severe traumatic brain injury: A retrospective analysis of the Japanese nationwide trauma registry.
    Naito K; Funakoshi H; Takahashi J
    Injury; 2023 Jan; 54(1):70-74. PubMed ID: 35934568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Blood Loss Greater in Elderly Patients under Antiplatelet or Anticoagulant Medication for Cervical Spine Injury Surgery? A Japanese Multicenter Survey.
    Uehara M; Ikegami S; Takizawa T; Oba H; Yokogawa N; Sasagawa T; Ando K; Nakashima H; Segi N; Funayama T; Eto F; Yamaji A; Watanabe K; Nori S; Takeda K; Furuya T; Orita S; Nakajima H; Yamada T; Hasegawa T; Terashima Y; Hirota R; Suzuki H; Imajo Y; Tonomura H; Sakata M; Hashimoto K; Onoda Y; Kawaguchi K; Haruta Y; Suzuki N; Kato K; Uei H; Sawada H; Nakanishi K; Misaki K; Terai H; Tamai K; Shirasawa E; Inoue G; Kakutani K; Kakiuchi Y; Kiyasu K; Tominaga H; Tokumoto H; Iizuka Y; Takasawa E; Akeda K; Takegami N; Funao H; Oshima Y; Kaito T; Sakai D; Yoshii T; Ohba T; Otsuki B; Seki S; Miyazaki M; Ishihara M; Okada S; Aoki Y; Harimaya K; Murakami H; Ishii K; Ohtori S; Imagama S; Kato S
    Spine Surg Relat Res; 2022; 6(4):366-372. PubMed ID: 36051672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking molecular interactions in membranes by simultaneous ATR-FTIR-AFM.
    Verity JE; Chhabra N; Sinnathamby K; Yip CM
    Biophys J; 2009 Aug; 97(4):1225-31. PubMed ID: 19686671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Antithrombotic Agents on Radiological Lesion Progression in Acute Traumatic Brain Injury: A CENTER-TBI Propensity-Matched Cohort Analysis.
    Mathieu F; Güting H; Gravesteijn B; Monteiro M; Glocker B; Kornaropoulos EN; Kamnistas K; Robertson CS; Levin H; Whitehouse DP; Das T; Lingsma HF; Maegele M; Newcombe VFJ; Menon DK;
    J Neurotrauma; 2020 Oct; 37(19):2069-2080. PubMed ID: 32312149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.